lorazepam has been researched along with Atrophy in 2 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 7.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 3.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "The diagnostic criteria of catatonia and frontotemporal dementia partly overlap." | 1.39 | Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy. ( Arai, H; Iseki, E; Utumi, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Utumi, Y | 1 |
| Iseki, E | 1 |
| Arai, H | 1 |
| Ubogu, EE | 1 |
| Sagar, SM | 1 |
| Lerner, AJ | 1 |
| Maddux, BN | 1 |
| Suarez, JI | 1 |
| Werz, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for lorazepam and Atrophy
| Article | Year |
|---|---|
Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy.
Topics: Aged; Atrophy; Catatonia; Combined Modality Therapy; Dopamine Agents; Electroconvulsive Therapy; Fem | 2013 |
Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.
Topics: Adult; Anticonvulsants; Atrophy; Brain; Electroencephalography; Excitatory Amino Acid Antagonists; H | 2003 |